Avalo Therapeutics FY 2024: revenue $441K, down 77%; diluted EPS −$20.91

Key figures from this report

These are the numbers Avalo Therapeutics reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$441K−77% from $1.9M in FY 202310-K income statement, on EDGAR
2. Net income−$35.1MAgainst −$31.5M in FY 202310-K income statement, on EDGAR
3. Diluted EPS−$20.91Against −$114.00 in FY 202310-K income statement, on EDGAR
4. Cash and cash equivalents$134.5M+1715% from $7.4M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations−$49.1MAgainst −$30.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables